TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05420584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial chemoembolization
Description: The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic MRI
Description: Pelvic MRI to evaluate efficacy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical resection of rectal cancer
Description: Surgical treatment for patients who meet the surgical conditions
Study: NCT04718285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Tablet
Description: 3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast plus Favicovir (Favipiravir)
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favicovir (Standard Treatment)
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
Study: NCT06459167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The position adopted when patients undergoing procedure or surgery
Description: For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The position adopted when patients undergoing procedure or surgery
Description: For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
Study: NCT05997563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Description: Vaginal micronized progesterone effervescent once daily until delivery
Study: NCT05950607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIN AD 2.0
Description: The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAIN AD 2.0
Description: The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. .
Study: NCT05709197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Description: Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Child reconstruction
Description: Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
Study: NCT05410587

Intervention type: DEVICE
Group type: OTHER
Intervention: Fracture Monitor (implantable device class III)
Description: Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
Study: NCT05369312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-442096
Description: Subjects will receive BPI-442096 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-442096
Description: Subjects will receive BPI-442096 until disease progression
Study: NCT04579094

Intervention type: OTHER
Intervention: Feces sampling at inclusion (J0)
Description: Feces sampling at inclusion (J0)

Intervention type: OTHER
Intervention: Feces sampling at inclusion (J0)
Description: Feces sampling at inclusion (J0)
Study: NCT04969965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aumolertinib
Description: EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
Study: NCT05904522

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy for histopathological examination

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy for histopathological examination
Study: NCT05815004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene therapy
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gene therapy
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
Study: NCT06285747

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT05815004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme Replacement Agent
Description: A hydrolytic lysosomal glucocerebrosidase-specific enzyme
Study: NCT05308589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPPF
Description: Continuous Postoperative Pericardial Flush
Study: NCT04899752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
Study: NCT06700070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA-0111
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT06699966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
Study: NCT06618976

Intervention type: DRUG
Group type: OTHER
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg, P.O. once daily for 1 month.

Intervention type: DRUG
Group type: OTHER
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg, P.O. once daily for 1 month.

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: Empagliflozin 10 mg, P.O. once daily for 1 month.

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: Empagliflozin 10 mg, P.O. once daily for 1 month.
Study: NCT04899752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
Study: NCT06208410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS105
Description: JS105 is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isetionate Tablets
Description: Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection (Albumin Bound)
Description: Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection (Albumin Bound)
Description: Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Capsules
Description: Fluzoparib Capsules is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate Tablets
Description: Pyrotinib Maleate Tablets is administered once daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Tablets
Description: Capecitabine Tablets is administered once daily, orally
Study: NCT05620160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216
Description: RAY1216（tablet）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo （tablet）
Study: NCT03689114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose carbamazepine
Description: Carbamazepine, 300 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose carbamazepine
Description: Carbamazepine 600 mg/die
Study: NCT05431920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (25-hydroxy vitamin D)
Description: Vitamin D3 oral supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D₃ (25-hydroxy vitamin D)
Description: Vitamin D3 oral supplementation
Study: NCT05454956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
Study: NCT04789161

Intervention type: PROCEDURE
Intervention: double kissing crush stenting
Description: Patients with true bifurcation lesion treating with double kissing crsuh stenting technique

Intervention type: PROCEDURE
Intervention: double kissing culotte stenting
Description: Patients with true bifurcation lesion treating with double kissing culotte stenting technique
Study: NCT05244577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets
Description: Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo,Ondansetron,Dexamethasone,Fosaprepitant
Study: NCT05396729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
Study: NCT05008731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: 100 units (0.5ml) in 1 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 ml in 1 injection
Study: NCT05461794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: administered intravenously
Study: NCT05168267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
Study: NCT05765149

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention will be implemented.
Study: NCT04815122

Intervention type: RADIATION
Intervention: SPECT TRODAT-1
Description: The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.

Intervention type: RADIATION
Intervention: SPECT TRODAT-1
Description: The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
Study: NCT03689114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose levetiracetam
Description: Levetiracetam 500 mg/die
Study: NCT06607081

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention
Description: The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
Study: NCT05118984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin capsule (Zithromax, Pfizer) (250 mg)
Description: Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment that has no active properties
Study: NCT03689114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose levetiracetam
Description: Levetiracetam 1000 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose valproate
Description: Valproate 300 mg/die
Study: NCT06276582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening for neonatal jaundice with a mobile health device
Description: Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
Study: NCT03689114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose valproate
Description: Valproate 600 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose zonisamide
Description: Zonisamide 150 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose zonisamide
Description: Zonisamide 300 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxcarbazepine
Description: Oxcarbazepine 600 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose oxcarbazepine
Description: Oxcarbazepine 1200 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose topiramate
Description: Topiramate 100 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose topiramate
Description: Topiramate 200 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose lamotrigine
Description: Lamotrigine 100 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose lamotrigine
Description: Lamotrigine 200 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose gabapentin
Description: Gabapentin 450 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose gabapentin
Description: Gabapentin 900 mg/die
Study: NCT05700760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)
Description: Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual (CAU)
Description: Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.